CN115353860B - Medical endoscope antifogging agent - Google Patents
Medical endoscope antifogging agent Download PDFInfo
- Publication number
- CN115353860B CN115353860B CN202211158953.1A CN202211158953A CN115353860B CN 115353860 B CN115353860 B CN 115353860B CN 202211158953 A CN202211158953 A CN 202211158953A CN 115353860 B CN115353860 B CN 115353860B
- Authority
- CN
- China
- Prior art keywords
- percent
- sodium
- antifogging agent
- medical endoscope
- endoscope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 11
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 229920000570 polyether Polymers 0.000 claims description 10
- 229920000223 polyglycerol Polymers 0.000 claims description 10
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 10
- 235000010234 sodium benzoate Nutrition 0.000 claims description 10
- 239000004299 sodium benzoate Substances 0.000 claims description 10
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 9
- 229940057950 sodium laureth sulfate Drugs 0.000 claims description 9
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- LGNQGTFARHLQFB-UHFFFAOYSA-N 1-dodecyl-2-phenoxybenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1OC1=CC=CC=C1 LGNQGTFARHLQFB-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 230000002335 preservative effect Effects 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000002562 thickening agent Substances 0.000 abstract description 2
- 239000000080 wetting agent Substances 0.000 abstract description 2
- 239000000306 component Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241000282887 Suidae Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000008358 core component Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- ZIWRUEGECALFST-UHFFFAOYSA-M sodium 4-(4-dodecoxysulfonylphenoxy)benzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCOS(=O)(=O)c1ccc(Oc2ccc(cc2)S([O-])(=O)=O)cc1 ZIWRUEGECALFST-UHFFFAOYSA-M 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Combustion & Propulsion (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Endoscopes (AREA)
Abstract
The invention discloses a medical endoscope antifogging agent, which relates to the technical field of antifogging agents, and aims to solve the problem that no suitable endoscope antifogging agent suitable for operation is available at present, and comprises the following components: surfactant, thickener, wetting agent, preservative and solvent, wherein each component is food-grade material.
Description
Technical Field
The invention relates to the technical field of antifogging agents, in particular to a medical endoscope antifogging agent.
Background
In the clinical course of medicine, lens fogging is a common phenomenon in the use of endoscopic surgery or examination, affecting diagnosis and treatment efficiency. The average fog time of the endoscopes used by the current medical institutions is 4-6 minutes, the surgical time of one surgical endoscope is about 26-90 minutes, the individual complex surgery can reach several hours, and the endoscopes are required to be extracted to repeatedly wipe fog in the process of each surgery, so that the progress and smoothness of the surgery are seriously affected. The current widely popular practices are: the hot water preheating method for the lens, the tissue omentum wiping method and the iodophor wiping method (the method has low cost, convenient operation and more use). Although antifogging agents are available on the market, they are not suitable for in vivo use due to toxicity, that is, there is no suitable endoscope defogging agent for surgical procedures.
Disclosure of Invention
The invention provides a medical endoscope antifogging agent, which comprises the following components: surfactant, thickener, wetting agent, preservative and solvent, wherein each component is food-grade material.
The invention is further provided with: the surfactant comprises at least one of fluorocarbon, sodium laureth sulfate, dioctyl sodium sulfosuccinate, sodium dodecyl sulfate and dodecyl diphenyl ether disulfonate.
The invention is further provided with: the components include: fluorocarbon, sodium chloride, sodium laureth sulfate, alkynol polyether, polyethylene glycol, dioctyl sodium sulfosuccinate, sodium dodecyl sulfate, dodecyl diphenyl ether disulfonate, sodium benzoate and deionized water.
The invention is further provided with: the novel antibacterial agent also comprises a synergistic antibacterial agent, wherein the synergistic antibacterial agent is polyglycerol ester.
The invention is further provided with: the components are as follows according to mass percent: 44 to 47 percent of fluorocarbon, 0.8 to 1.3 percent of sodium chloride, 4.5 to 6.5 percent of sodium laureth sulfate, 4.5 to 5.5 percent of alkynol polyether, 1.4 to 1.6 percent of polyethylene glycol, 0.3 to 0.5 percent of dioctyl sodium sulfosuccinate, 0.4 to 0.6 percent of sodium dodecyl sulfate, 0.3 to 0.5 percent of dodecyl diphenyl ether disulfonate, 0.2 to 0.4 percent of sodium benzoate, 3.5 to 4.5 percent of polyglycerol ester, 31 to 36 percent of deionized water and essence: the balance.
The beneficial effects of the invention are as follows:
the core components in the formula of the invention are the mixture of fluorocarbon, alkynol polyether, sodium benzoate and polyglycerol ester, and the four components have synergistic effect, and under a specific proportion, the endoscope lens has extremely strong hydrophobicity and oleophobicity, and can be ensured to be kept clear for a long time in the use process.
Detailed Description
Preferred embodiments of the present invention are described below. It should be understood by those skilled in the art that these embodiments are merely for explaining the technical principles of the present invention, and are not intended to limit the scope of the present invention.
Example 1
The medical endoscope antifogging agent provided by the embodiment is prepared from 100g of sample, and comprises the following components in parts by weight: 45% of fluorocarbon, 1.2% of sodium chloride, 6.1% of sodium laureth sulfate, 5.2% of alkynol polyether, 1.5% of polyethylene glycol, 0.4% of dioctyl sodium sulfosuccinate, 0.5% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0.4% of sodium benzoate, 4.5% of polyglycerol ester, 34% of deionized water and essence: the balance.
All the above components are required to be food grade.
Comparative test 1
Experiment place: beijing city Pinggu animal simulation hospital
Experimental animals: young pig
Overview of the experiment: according to the principles of similarity, reliability and economy, young pigs close to human body temperature are selected as experimental objects, and the experiment is carried out by using a simulation hospital to regularly train doctors from hospitals in various provinces and markets nationwide in the treatment of uterine and laparoscopic surgery such as gynecology and urology surgery.
Experiment design: three (3) simulated operating rooms are prepared, and each simulated operating room is respectively provided with two sets of endoscopic operating equipment. 6 young pigs were randomly selected and numbered 1-6 one by one. Three young pigs numbered 1, 2 and 3 are used as a control group, and an iodophor is used for wiping the endoscope lens; three young pigs numbered 4, 5, 6 were used as experimental groups and the medical endoscope antifogging agent wiping lens of example 1 was used.
The experimental process comprises the following steps: the simulated operating room temperature was 22 ℃, the expected anesthetic time for young pigs was 90 minutes, and medical staff were wiped the lenses with iodophor and the medical endoscope antifogging agent of example 1, respectively, and then operated during normal use of monopolar and bipolar probes, and electrically peeled and cut tissues in the pigs. If the young pigs are about to wake, small-dose anesthesia is added, and meanwhile, a doctor finishes the operation as soon as possible; in the process, the time of the phenomenon of fog and bead formation of the endoscope lens caused by the high-temperature and high-humidity pig internal environment is recorded, the lens is wiped after recording, the corresponding reagent is smeared, and the recording is restarted for 10 times.
Fog assessment criteria: the general experience of clinically judging the fogging of an endoscope lens is that one quarter of the area seen by a visual field is in a pasty state or the central part is only in a slightly pasty state, namely the fogging is generated.
Experimental data are as follows:
by data comparison, the medical endoscope antifogging agent in the embodiment can be obviously improved in antifogging time.
Example 2
The medical endoscope antifogging agent provided by the embodiment is prepared from 100g of sample, and comprises the following components in parts by weight: 44% of fluorocarbon, 1.2% of sodium chloride, 6.1% of sodium laureth sulfate, 5.2% of alkynol polyether, 1.5% of polyethylene glycol, 0.4% of dioctyl sodium sulfosuccinate, 0.5% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0.4% of sodium benzoate, 4.5% of polyglycerol ester, 35% of deionized water and essence: the balance.
Example 3
The medical endoscope antifogging agent provided by the embodiment is prepared from 100g of sample, and comprises the following components in parts by weight: 47% of fluorocarbon, 1.2% of sodium chloride, 6.1% of sodium laureth sulfate, 5.2% of alkynol polyether, 1.5% of polyethylene glycol, 0.4% of dioctyl sodium sulfosuccinate, 0.5% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0.4% of sodium benzoate, 4.5% of polyglycerol ester, 32% of deionized water and essence: the balance.
Comparative example 1
The medical endoscope antifogging agent provided by the comparative example is prepared from 100g of sample, and comprises the following components in parts by weight: 47% of fluorocarbon, 1.2% of sodium chloride, 6.1% of sodium laureth sulfate, 0% of alkynol polyether, 1.5% of polyethylene glycol, 0.4% of dioctyl sodium sulfosuccinate, 0.5% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0% of sodium benzoate, 0% of polyglycerol ester, 42.1% of deionized water and essence: the balance.
Comparative example 2
The medical endoscope antifogging agent provided by the embodiment is prepared from 100g of sample, and comprises the following components in parts by weight: 0% of fluorocarbon, 1.3% of sodium chloride, 6.5% of sodium laureth sulfate, 5.5% of alkynol polyether, 1.6% of polyethylene glycol, 0.5% of dioctyl sodium sulfosuccinate, 0.6% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0.4% of sodium benzoate, 4.5% of polyglycerol ester, 78% of deionized water and essence: the balance.
Comparative experiment 2
Referring to comparative experiment 1, 5 young pigs were selected, and the reagents prepared in examples 1 to 3 and comparative examples 1 to 2 were applied to the endoscope head, respectively, and the fogging time was recorded eight times during the simulated surgery teaching.
The experimental data are shown in Table 2
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
| Example 1 | 32 | 34 | 35 | 33 | 37 | 37 | 36 | 37 |
| Example 2 | 31 | 27 | 27 | 29 | 32 | 30 | 30 | 32 |
| Example 3 | 21 | 19 | 24 | 23 | 21 | 20 | 19 | 20 |
| Comparative example 1 | 12 | 10 | 13 | 12 | 9 | 11 | 14 | 12 |
| Comparative example 2 | 11 | 9 | 9 | 12 | 11 | 10 | 10 | 11 |
From the data, the core components in the formula of the invention are the mixture of fluorocarbon, alkynol polyether, sodium benzoate and polyglycerol ester, and the four components are synergistic, so that the endoscope lens has extremely strong hydrophobicity and oleophobicity under a specific proportion, and can be ensured to be kept clear for a long time in the use process. The four functions can be better performed by strict proportion.
While the invention has been described with reference to a preferred embodiment, various modifications may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention, and in particular, the technical features set forth in the various embodiments may be combined in any manner so long as there is no structural conflict. The present invention is not limited to the specific embodiments disclosed herein, but encompasses all technical solutions falling within the scope of the claims.
Claims (1)
1. The medical endoscope antifogging agent is characterized by comprising the following components in percentage by mass: 44 to 47 percent of fluorocarbon, 0.8 to 1.3 percent of sodium chloride, 4.5 to 6.5 percent of sodium laureth sulfate, 4.5 to 5.5 percent of alkynol polyether, 1.4 to 1.6 percent of polyethylene glycol, 0.3 to 0.5 percent of dioctyl sodium sulfosuccinate, 0.4 to 0.6 percent of sodium dodecyl sulfate, 0.3 to 0.5 percent of dodecyl diphenyl ether disulfonate, 0.2 to 0.4 percent of sodium benzoate, 3.5 to 4.5 percent of polyglycerol ester, 31 to 36 percent of deionized water and essence: the balance; each component is food-grade material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211158953.1A CN115353860B (en) | 2022-09-22 | 2022-09-22 | Medical endoscope antifogging agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211158953.1A CN115353860B (en) | 2022-09-22 | 2022-09-22 | Medical endoscope antifogging agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115353860A CN115353860A (en) | 2022-11-18 |
| CN115353860B true CN115353860B (en) | 2024-01-02 |
Family
ID=84007336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211158953.1A Active CN115353860B (en) | 2022-09-22 | 2022-09-22 | Medical endoscope antifogging agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115353860B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6296694B1 (en) * | 1998-06-25 | 2001-10-02 | Roger Machson | Transparent anti-fog anti-splash coating compositions |
| CN104477139A (en) * | 2014-12-23 | 2015-04-01 | 扬州倍加洁日化有限公司 | Automobile glass cleaning and defrosting antifogging wet tissue and processing method thereof |
| CN106833524A (en) * | 2016-12-28 | 2017-06-13 | 于文 | Glass pane antifoggant and preparation method thereof in automobile |
| CN111196916A (en) * | 2018-11-20 | 2020-05-26 | 上海昕光医疗科技有限公司 | Medical antifogging agent and preparation method thereof |
| CN111574960A (en) * | 2020-05-12 | 2020-08-25 | 浙江优亿医疗器械有限公司 | Formula and preparation method of antifogging liquid |
| CN111592856A (en) * | 2020-05-08 | 2020-08-28 | 南京普莱斯医疗器材有限公司 | Visual field clearing agent for medical endoscope and preparation method thereof |
| CN113105868A (en) * | 2021-04-19 | 2021-07-13 | 江苏南创化学与生命健康研究院有限公司 | Antibacterial antifogging agent and antibacterial long-acting antifogging wet tissue prepared from same |
-
2022
- 2022-09-22 CN CN202211158953.1A patent/CN115353860B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6296694B1 (en) * | 1998-06-25 | 2001-10-02 | Roger Machson | Transparent anti-fog anti-splash coating compositions |
| CN104477139A (en) * | 2014-12-23 | 2015-04-01 | 扬州倍加洁日化有限公司 | Automobile glass cleaning and defrosting antifogging wet tissue and processing method thereof |
| CN106833524A (en) * | 2016-12-28 | 2017-06-13 | 于文 | Glass pane antifoggant and preparation method thereof in automobile |
| CN111196916A (en) * | 2018-11-20 | 2020-05-26 | 上海昕光医疗科技有限公司 | Medical antifogging agent and preparation method thereof |
| CN111592856A (en) * | 2020-05-08 | 2020-08-28 | 南京普莱斯医疗器材有限公司 | Visual field clearing agent for medical endoscope and preparation method thereof |
| CN111574960A (en) * | 2020-05-12 | 2020-08-25 | 浙江优亿医疗器械有限公司 | Formula and preparation method of antifogging liquid |
| CN113105868A (en) * | 2021-04-19 | 2021-07-13 | 江苏南创化学与生命健康研究院有限公司 | Antibacterial antifogging agent and antibacterial long-acting antifogging wet tissue prepared from same |
Non-Patent Citations (1)
| Title |
|---|
| 张天胜.《表面活性剂应用技术》.化学工业出版社,(第1版),224. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115353860A (en) | 2022-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fan et al. | Minimally invasive video-assisted thyroidectomy: experience of 300 cases | |
| Zhou et al. | The intranasal endoscopic removal of schwannoma of the pterygopalatine and infratemporal fossae via the prelacrimal recess approach | |
| US11847932B2 (en) | Modified animal organs for use in surgical simulators | |
| Cheng et al. | Robotic-assisted laparoscopic complex myomectomy: a single medical center's experience | |
| Yadav et al. | Practical aspects of neuroendoscopic techniques and complication avoidance: a systematic review | |
| CN115353860B (en) | Medical endoscope antifogging agent | |
| Sánchez‐Margallo et al. | Preliminary application of a single‐port access technique for laparoscopic ovariohysterectomy in dogs | |
| Regmi et al. | Endoscopic endonasal transsphenoidal approach to pituitary adenoma: A multi-disciplinary approach | |
| Tan et al. | Endoscopic transnasal approach to medial orbital lesions | |
| Martinez et al. | Transfer of acquired practical skills from dry lab into live surgery using the avatera robotic system: An experimental study | |
| EP3345478A1 (en) | Clinical cadaver simulator | |
| Zhang et al. | Pros and cons of transoral endoscopic thyroidectomy via vestibular approach: a comparative study | |
| Bain et al. | Endoscopic excision of supracondylar humeral spur for decompression of the median nerve and brachial artery | |
| RU2228718C1 (en) | Method for low-invasive surgical treatment of large and giant tumors of cranial foundation of endo-extracellular localization | |
| Kocbek et al. | Thiel's embalming method: review of the literature and our institute's experience | |
| Padilla et al. | Proposal of a New Minimally Invasive Technique for Latissimus Dorsi Muscle Harvest | |
| Hawkes et al. | Improving Techniques to Study Equine Cervical Mucociliary Clearance | |
| Adayener et al. | Does prior laparoscopic and open surgery experience have any impact on learning curve in transition to robotic surgery? | |
| Fani | Abstracts of the joint ALLSA, SATS and CWIG Congress in Pretoria, July 2019 | |
| Maitiyasen et al. | Robot-Assisted Thoracic Surgery for benign tumors at the cervicothoracic junction: A retrospective study | |
| Shufen et al. | Characteristics of lingual thyroglossal duct cysts under flexible laryngoscopy and treatment approaches | |
| Cable et al. | Pediatric otolaryngology | |
| Fournier | Endoscopie in cranial neurosurgery L'endoscope en neurochirurgie crânienne | |
| Zhou et al. | Aortic Arch Stenosis Caused by Minimally Invasive Surgery in Mouse Heart Failure Model. | |
| Lúcio Gomes et al. | New Technique for Intrathoracic Implantation of Extraluminal Spiral Prostheses in the Trachea. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |